These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Cardiac arrhythmias, anti-arrhythmic drugs and prostaglandins. Das UN J Indian Med Assoc; 1980 Jan; 74(1):23-4. PubMed ID: 7229395 [No Abstract] [Full Text] [Related]
23. [Relation between the serum concentration and the clinical effectiveness of anti-arrhythmia agents]. Follath F Cardiology; 1983; 70 Suppl 1():108-13. PubMed ID: 6342777 [No Abstract] [Full Text] [Related]
24. [The effects of propafenone in the treatment of ventricular arrhythmias with a malignant potential for resistance to conventional anti-arrhythmia medication]. Câmpeanu A; Rădoi M; Serban-Pârâu G; Pleşca O; Nuţă M; Teodorescu V; Titirigă M Med Interna; 1993; 45(1-2):35-41. PubMed ID: 8081689 [No Abstract] [Full Text] [Related]
25. [Amiodarone in the treatment of arrhythmias]. Raatikainen MJ; Huikuri HV Duodecim; 1998; 114(19):1923-36. PubMed ID: 11717746 [No Abstract] [Full Text] [Related]
31. Model systems for the discovery and development of antiarrhythmic drugs. Nattel S; Duker G; Carlsson L Prog Biophys Mol Biol; 2008; 98(2-3):328-39. PubMed ID: 19038282 [TBL] [Abstract][Full Text] [Related]
33. Is there a need for new antiarrhythmic drugs? Roden DM Arch Mal Coeur Vaiss; 1996 Feb; 89 Spec No 1():13-8. PubMed ID: 8734158 [TBL] [Abstract][Full Text] [Related]
34. [The effect of naloxone on rhythm disorders and on the conduction system of the heart]. Shliakhto EV; Zaĭtsev AA; Panov AV; Ardashev AV; Nifontov EM; Kashina EA; Kazarin VV; Ivanov VV Eksp Klin Farmakol; 1996; 59(3):34-6. PubMed ID: 8974581 [TBL] [Abstract][Full Text] [Related]
35. [Proarrhythmic effects of anti-arrhythmia agents]. Enrico JF; Kehtari R Rev Med Suisse Romande; 1998 Aug; 118(8):671-90. PubMed ID: 9838826 [No Abstract] [Full Text] [Related]
36. Effects of purified endogenous inhibitor of the Na+/Ca2+ exchanger on ouabain-induced arrhythmias in the atria and ventricle strips of guinea pig. Shpak B; Gofman Y; Shpak C; Hiller R; Boyman L; Khananshvili D Eur J Pharmacol; 2006 Dec; 553(1-3):196-204. PubMed ID: 17078946 [TBL] [Abstract][Full Text] [Related]
37. [Determination of plasma levels of cardiovascular anti-arrhythmia drugs. Technical aspects and clinical prospectives]. Paoletti V; Galeotta G; Faletra E; Cavina G; Mammarella A Clin Ter; 1987 Mar; 120(6):529-37. PubMed ID: 2954745 [No Abstract] [Full Text] [Related]
38. How do pharmacokinetics relate to pharmacodynamics of antiarrhythmic drugs? Shanks RG Eur Heart J; 1988 Feb; 9 Suppl B():51-6. PubMed ID: 3286268 [No Abstract] [Full Text] [Related]
39. [Significance of magnesium in cardiac arrhythmias]. Stühlinger HG; Kiss K; Smetana R Wien Med Wochenschr; 2000; 150(15-16):330-4. PubMed ID: 11105328 [TBL] [Abstract][Full Text] [Related]
40. [Lidocaine as an anti-arrhythmia agent. The pharmacological, experimental and clinical background for its use]. Flensted-Jensen E Ugeskr Laeger; 1969 Mar; 131(12):500-4. PubMed ID: 5793604 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]